invasive cytology based assay, is
designed for cancer screening of large populations at a reasonable cost.
Current diagnostic methods for lung cancer, including CT scans and X-rays,
often detect the disease only at more advanced stages and are relatively
expensive.
Lung cancer claims more lives than any other cancer. The expected
5-year survival rate for all patients combined in whom lung cancer is
diagnosed is 15 percent and by contrast, the 5-year survival rate for cases
detected when the disease is still localized is 50 percent. At the present
time, only 16 percent of lung cancer cases are diagnosed at this early
stage.
Contact: John Cousins
(505) 821-0875
'/>"/>SOURCE Biomoda, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 Related biology technology :1.
WallSt.net Announces Upcoming Interview With CEO of Biomoda2.
Biomoda Hires Manzano Strategies LLC to Spearhead Government Affairs Efforts3.
Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.4.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients5.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 266.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering7.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.8.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets9.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results10.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain11.
Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter